Clinical Trials
6 trialsNCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT05439499 2022-07-06
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed